Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CD23 and B cell activation.

Literature DB >> 1533341

CD23 and B cell activation.

J Gordon¹.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 1992 PMID： 1533341 DOI： 10.1111/j.1365-2222.1992.tb03073.x

Source DB: PubMed Journal: Clin Exp Allergy ISSN： 0954-7894 Impact factor: 5.018

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

1. Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma.

Authors: M P Purdue; Q Lan; T J Kemp; A Hildesheim; S J Weinstein; J N Hofmann; J Virtamo; D Albanes; L A Pinto; N Rothman
Journal: Leukemia Date: 2014-01-08 Impact factor: 11.528

2. Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation.

Authors: K T Hall; L Boumsell; J L Schultze; V A Boussiotis; D M Dorfman; A A Cardoso; A Bensussan; L M Nadler; G J Freeman
Journal: Proc Natl Acad Sci U S A Date: 1996-10-15 Impact factor: 11.205

3. Serum soluble CD23 in patients with hypogammaglobulinaemia.

Authors: A S Bansal; M R Haeney; S Cochrane; R S Pumphrey; L M Green; M Bhavnani; P B Wilson
Journal: Clin Exp Immunol Date: 1994-08 Impact factor: 4.330

4. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.

Authors: Elizabeth Crabb Breen; Shehnaz K Hussain; Larry Magpantay; Lisa P Jacobson; Roger Detels; Charles S Rabkin; Richard A Kaslow; Daina Variakojis; Jay H Bream; Charles R Rinaldo; Richard F Ambinder; Otoniel Martinez-Maza
Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-04-28 Impact factor: 4.254

5. Inhibition by glucocorticoid and staurosporine of IL-4-dependent CD23 production in B lymphocytes is reversed on engaging CD40.

Authors: A Katira; K A Knox; M Finney; R H Michell; M Wakelam; J Gordon
Journal: Clin Exp Immunol Date: 1993-05 Impact factor: 4.330

10. Shigella infection induces cellular activation of T and B cells and distinct species-related changes in peripheral blood lymphocyte subsets during the course of the disease.

Authors: D Islam; P K Bardhan; A A Lindberg; B Christensson
Journal: Infect Immun Date: 1995-08 Impact factor: 3.441

CD23 and B cell activation.

1. Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma.

2. Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation.

3. Serum soluble CD23 in patients with hypogammaglobulinaemia.

4. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.

5. Inhibition by glucocorticoid and staurosporine of IL-4-dependent CD23 production in B lymphocytes is reversed on engaging CD40.

6. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.

7. Variations in serum sCD23 in conditions with either enhanced humoral or cell-mediated immunity.

8. Distinct modulation by interferon-gamma (IFN-gamma) of CD23 expression on B and T lymphocytes of atopic subjects.

9. Serum measurements of soluble CD23 in HIV infection.

10. Shigella infection induces cellular activation of T and B cells and distinct species-related changes in peripheral blood lymphocyte subsets during the course of the disease.